SMA
EPZM

Sage Mountain Advisors’s Epizyme, Inc EPZM Stock Holding History

Sage Mountain Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,273
Closed -$124K – 720
2021
Q3 		$124K Buy
+24,273
New +$147K 0.02% 479

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Sage Mountain Advisors's EPZM Position: Q4 2021 in Review

Sage Mountain Advisors sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 24,273 shares — an estimated $124K sold.

Sage Mountain Advisors first reported a position in EPZM in Q3 2021 and held it in 1 quarter. The position peaked at $124K in Q3 2021. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Sage Mountain Advisors reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Sage Mountain Advisors sold 24,273 Epizyme, Inc shares in Q4 2021, an estimated $124K.
  • Sage Mountain Advisors first reported a position in Epizyme, Inc in Q3 2021 and held it in 1 quarter.
  • Sage Mountain Advisors's Epizyme, Inc position peaked at $124K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Sage Mountain Advisors's 13F filing for Q4 2021, filed 2 Feb 2022.